Cargando…
Effects of early-life antibiotics on the developing infant gut microbiome and resistome: a randomized trial
Broad-spectrum antibiotics for suspected early-onset neonatal sepsis (sEONS) may have pronounced effects on gut microbiome development and selection of antimicrobial resistance when administered in the first week of life, during the assembly phase of the neonatal microbiome. Here, 147 infants born a...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8850541/ https://www.ncbi.nlm.nih.gov/pubmed/35173154 http://dx.doi.org/10.1038/s41467-022-28525-z |
_version_ | 1784652619687395328 |
---|---|
author | Reyman, Marta van Houten, Marlies A. Watson, Rebecca L. Chu, Mei Ling J. N. Arp, Kayleigh de Waal, Wouter J. Schiering, Irene Plötz, Frans B. Willems, Rob J. L. van Schaik, Willem Sanders, Elisabeth A. M. Bogaert, Debby |
author_facet | Reyman, Marta van Houten, Marlies A. Watson, Rebecca L. Chu, Mei Ling J. N. Arp, Kayleigh de Waal, Wouter J. Schiering, Irene Plötz, Frans B. Willems, Rob J. L. van Schaik, Willem Sanders, Elisabeth A. M. Bogaert, Debby |
author_sort | Reyman, Marta |
collection | PubMed |
description | Broad-spectrum antibiotics for suspected early-onset neonatal sepsis (sEONS) may have pronounced effects on gut microbiome development and selection of antimicrobial resistance when administered in the first week of life, during the assembly phase of the neonatal microbiome. Here, 147 infants born at ≥36 weeks of gestational age, requiring broad-spectrum antibiotics for treatment of sEONS in their first week of life were randomized 1:1:1 to receive three commonly prescribed intravenous antibiotic combinations, namely penicillin + gentamicin, co-amoxiclav + gentamicin or amoxicillin + cefotaxime (ZEBRA study, Trial Register NL4882). Average antibiotic treatment duration was 48 hours. A subset of 80 non-antibiotic treated infants from a healthy birth cohort served as controls (MUIS study, Trial Register NL3821). Rectal swabs and/or faeces were collected before and immediately after treatment, and at 1, 4 and 12 months of life. Microbiota were characterized by 16S rRNA-based sequencing and a panel of 31 antimicrobial resistance genes was tested using targeted qPCR. Confirmatory shotgun metagenomic sequencing was executed on a subset of samples. The overall gut microbial community composition and antimicrobial resistance gene profile majorly shift directly following treatment (R(2 )= 9.5%, adjusted p-value = 0.001 and R(2 )= 7.5%, adjusted p-value = 0.001, respectively) and normalize over 12 months (R(2) = 1.1%, adjusted p-value = 0.03 and R(2 )= 0.6%, adjusted p-value = 0.23, respectively). We find a decreased abundance of Bifidobacterium spp. and increased abundance of Klebsiella and Enterococcus spp. in the antibiotic treated infants compared to controls. Amoxicillin + cefotaxime shows the largest effects on both microbial community composition and antimicrobial resistance gene profile, whereas penicillin + gentamicin exhibits the least effects. These data suggest that the choice of empirical antibiotics is relevant for adverse ecological side-effects. |
format | Online Article Text |
id | pubmed-8850541 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-88505412022-03-04 Effects of early-life antibiotics on the developing infant gut microbiome and resistome: a randomized trial Reyman, Marta van Houten, Marlies A. Watson, Rebecca L. Chu, Mei Ling J. N. Arp, Kayleigh de Waal, Wouter J. Schiering, Irene Plötz, Frans B. Willems, Rob J. L. van Schaik, Willem Sanders, Elisabeth A. M. Bogaert, Debby Nat Commun Article Broad-spectrum antibiotics for suspected early-onset neonatal sepsis (sEONS) may have pronounced effects on gut microbiome development and selection of antimicrobial resistance when administered in the first week of life, during the assembly phase of the neonatal microbiome. Here, 147 infants born at ≥36 weeks of gestational age, requiring broad-spectrum antibiotics for treatment of sEONS in their first week of life were randomized 1:1:1 to receive three commonly prescribed intravenous antibiotic combinations, namely penicillin + gentamicin, co-amoxiclav + gentamicin or amoxicillin + cefotaxime (ZEBRA study, Trial Register NL4882). Average antibiotic treatment duration was 48 hours. A subset of 80 non-antibiotic treated infants from a healthy birth cohort served as controls (MUIS study, Trial Register NL3821). Rectal swabs and/or faeces were collected before and immediately after treatment, and at 1, 4 and 12 months of life. Microbiota were characterized by 16S rRNA-based sequencing and a panel of 31 antimicrobial resistance genes was tested using targeted qPCR. Confirmatory shotgun metagenomic sequencing was executed on a subset of samples. The overall gut microbial community composition and antimicrobial resistance gene profile majorly shift directly following treatment (R(2 )= 9.5%, adjusted p-value = 0.001 and R(2 )= 7.5%, adjusted p-value = 0.001, respectively) and normalize over 12 months (R(2) = 1.1%, adjusted p-value = 0.03 and R(2 )= 0.6%, adjusted p-value = 0.23, respectively). We find a decreased abundance of Bifidobacterium spp. and increased abundance of Klebsiella and Enterococcus spp. in the antibiotic treated infants compared to controls. Amoxicillin + cefotaxime shows the largest effects on both microbial community composition and antimicrobial resistance gene profile, whereas penicillin + gentamicin exhibits the least effects. These data suggest that the choice of empirical antibiotics is relevant for adverse ecological side-effects. Nature Publishing Group UK 2022-02-16 /pmc/articles/PMC8850541/ /pubmed/35173154 http://dx.doi.org/10.1038/s41467-022-28525-z Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Reyman, Marta van Houten, Marlies A. Watson, Rebecca L. Chu, Mei Ling J. N. Arp, Kayleigh de Waal, Wouter J. Schiering, Irene Plötz, Frans B. Willems, Rob J. L. van Schaik, Willem Sanders, Elisabeth A. M. Bogaert, Debby Effects of early-life antibiotics on the developing infant gut microbiome and resistome: a randomized trial |
title | Effects of early-life antibiotics on the developing infant gut microbiome and resistome: a randomized trial |
title_full | Effects of early-life antibiotics on the developing infant gut microbiome and resistome: a randomized trial |
title_fullStr | Effects of early-life antibiotics on the developing infant gut microbiome and resistome: a randomized trial |
title_full_unstemmed | Effects of early-life antibiotics on the developing infant gut microbiome and resistome: a randomized trial |
title_short | Effects of early-life antibiotics on the developing infant gut microbiome and resistome: a randomized trial |
title_sort | effects of early-life antibiotics on the developing infant gut microbiome and resistome: a randomized trial |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8850541/ https://www.ncbi.nlm.nih.gov/pubmed/35173154 http://dx.doi.org/10.1038/s41467-022-28525-z |
work_keys_str_mv | AT reymanmarta effectsofearlylifeantibioticsonthedevelopinginfantgutmicrobiomeandresistomearandomizedtrial AT vanhoutenmarliesa effectsofearlylifeantibioticsonthedevelopinginfantgutmicrobiomeandresistomearandomizedtrial AT watsonrebeccal effectsofearlylifeantibioticsonthedevelopinginfantgutmicrobiomeandresistomearandomizedtrial AT chumeilingjn effectsofearlylifeantibioticsonthedevelopinginfantgutmicrobiomeandresistomearandomizedtrial AT arpkayleigh effectsofearlylifeantibioticsonthedevelopinginfantgutmicrobiomeandresistomearandomizedtrial AT dewaalwouterj effectsofearlylifeantibioticsonthedevelopinginfantgutmicrobiomeandresistomearandomizedtrial AT schieringirene effectsofearlylifeantibioticsonthedevelopinginfantgutmicrobiomeandresistomearandomizedtrial AT plotzfransb effectsofearlylifeantibioticsonthedevelopinginfantgutmicrobiomeandresistomearandomizedtrial AT willemsrobjl effectsofearlylifeantibioticsonthedevelopinginfantgutmicrobiomeandresistomearandomizedtrial AT vanschaikwillem effectsofearlylifeantibioticsonthedevelopinginfantgutmicrobiomeandresistomearandomizedtrial AT sanderselisabetham effectsofearlylifeantibioticsonthedevelopinginfantgutmicrobiomeandresistomearandomizedtrial AT bogaertdebby effectsofearlylifeantibioticsonthedevelopinginfantgutmicrobiomeandresistomearandomizedtrial |